Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

5-Aminosalicylates do not change renal function in Crohn's

November's issue of Inflammatory Bowel Diseases shows that cumulative dose of 5-aminosalicylates is not a predictor for renal function change, but still advocates serum creatinine measurements pre- and during treatment.

News image

fiogf49gjkf04

Case reports concerning irreversible renal failure caused by 5-aminosalicylates have been published.

Dr de Jong and colleagues investigated the effect of long-term use of 5-aminosalicylates on renal function in patients with Crohn's disease.

The researchers conducted a retrospective survey in 200 consecutive outpatients with Crohn's disease.

Endogenous creatinine clearance was estimated from serum creatinine with the Cockroft and Gault formula.

The first endogenous creatinine clearance was chosen close to the start of 5-aminosalicylates.

The second was the most recent endogenous creatinine clearance available.

The research team reported that in 153 patients, of which 59 were men and 94 were women, sufficient data were available for analysis.

The team noted that the interval between endogenous creatinine clearance was 11 years, with a mean exposure to 5-aminosalicylates of 9 years.

The mean decline in endogenous creatinine clearance was 0.3 mL/min/yr with Crohn's
Inflammatory Bowel Diseases

The cumulative dose of 5-aminosalicylates amounted to 9 kg.

The researchers observed that the endogenous creatinine clearance declined from 100 to 92 mL/min, at a rate of 0.3 mL/min/yr.

In a multiple linear regression model, duration of the interval was a significant predictor for change in endogenous creatinine clearance.

However, the team noted that cumulative dose of 5-aminosalicylates was not predictive of change in endogenous creatinine clearance.

No interstitial nephritis was reported.

The team found that, in the 8 patients with the largest decline in endogenous creatinine clearance, comorbidity causing renal function impairment was present.

Dr de Jong's team concluded, “The mean decline in endogenous creatinine clearance of 0.3 mL/min/yr in patients with Crohn's disease does not exceed the decline expected from physiologic aging.”

“Furthermore, the cumulative dose of 5-aminosalicylates was not a predictor for change in renal function.”

“However, as interstitial nephritis caused by 5-aminosalicylates may rarely occur, we still advocate measurements of serum creatinine before and during treatment.”

Inflamm Bowel Dis 2005: 11(11):972-976
27 October 2005

Go to top of page Email this page Email this page to a colleague

 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us